A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.

Fine, Howard; Reid, Tony; Caroen, Scott; Oronsky, Bryan; Abrouk, Nacer; Butowski, Nicholas

Fine, Howard; Reid, Tony; Caroen, Scott; Oronsky, Bryan; Abrouk, Nacer; Butowski, Nicholas.

Afiliação

Fine H; Department of Neuro-oncology, Brain Tumor Center at New York-Presbyterian Weill Cornell Medical Center, New York, NY, United States.
Reid T; Department of Oncology, EpicentRx, Torrey Pines, CA, United States.
Caroen S; Department of Drug Development, Clinical Trial Innovations, Mountain View, CA, United States.
Oronsky B; Department of Drug Development, Clinical Trial Innovations, Mountain View, CA, United States.
Abrouk N; Department of Drug Development, Clinical Trial Innovations, Mountain View, CA, United States.
Butowski N; Department of Neuro-oncology, UCSF Brain Tumor Center, San Francisco, CA, United States.

Front Oncol ; 13: 1176448, 2023.

Article em En | MEDLINE | ID: mdl-37342189

Palavras-chave

RRx-001; brain penetrant; hypoxia activated; primary GBM; radiotherapy; temozolomide (not in MeSH)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google